EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics Holdings announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.
EKF Diagnostics Holdings plc provides shareholders with the following update on current trading.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 (the "Previous Announcement") and confirms that with effect from 22 December 2017 it will cancel 78,113 of the 205,561 Compensation Shares (as defined in the Previous Announcement (the "Cancellation").
EKF Diagnostics Holdings plc confirms that the 6,630,032 will be cancelled.
As at 31 October 2017, the Company's total issued share capital consists of 458,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds 1,000,000 Ordinary Shares in treasury.
Standard form for notification of major holdings
EKF Diagnostics announces an update to its prior announcement on 6 November 2015 in relation to the settlement agreement reached with the majority of the former shareholders of Selah.
EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2017.
EKF Diagnostics Holdings plc announces that the reduction of the Company's share capital has now been approved by the court.
EKF Diagnostics Holdings plc announces that it will release its interim results for the six months ended 30 June 2017 on Monday 11 September 2017.